Literature DB >> 16189182

GnRH-II receptor-like antigenicity in human placenta and in cancers of the human reproductive organs.

Nicola Eicke1, Andreas R Günthert, Volker Viereck, Doreen Siebold, Martin Béhé, Tamara Becker, Günter Emons, Carsten Gründker.   

Abstract

We have recently demonstrated that the antiproliferative activity of GnRH-II on human endometrial and ovarian cancer cell lines is not mediated through the GnRH-I receptor. A functional receptor for human GnRH-II has not yet been identified. In this study, we have generated a polyclonal antiserum to the putative human GnRH-II receptor using a peptide (YSPTMLTEVPPC) corresponding to the third extracellular domain coupled to keyhole limpet haemocyanin via the Cys residue. A database search showed no identical peptide sequences in any other human gene. To avoid cross-reactions against two similar amino acid sequences the antiserum was pre-absorbed using these peptides. Immune histological sections of human placenta and human endometrial, ovarian and prostate cancers using rabbit anti-human GnRH-II receptor antiserum showed GnRH-II receptor-like staining. Western blot analysis of cell membrane preparations of human endometrial and ovarian cancer cell lines yielded a band at approximately 43 kDa whereas Western blot analysis of cell membrane preparations of ovaries obtained from the marmoset monkey (Callithrix jacchus) yielded a band at approximately 54 kDa. To identify the GnRH-II receptor-like antigen we used the photo-affinity labelling technique. Photochemical reaction of (125)I-labelled (4-azidobenzoyl)-N-hydroxysuccinimide-[d-Lys(6)]-GnRH-II (10(-9) M) with cell membrane preparations of human endometrial and ovarian cancer cells yielded a band at approximately 43 kDa. In competition experiments, the GnRH-I agonist Triptorelin (10(-7) M) showed a weak decrease of (125)I-labelled (4-azidobenzoyl)-N-hydroxysuccinimide-[d-Lys(6)]-GnRH-II binding to its binding site. The GnRH-I antagonist Cetrorelix (10(-7) M) showed a clearly stronger decrease, whereas GnRH-II agonist [d-Lys(6)]-GnRH-II (10(-7) M) was the most potent competitor. Western blot analysis of the same gel using rabbit anti-human GnRH-II receptor antiserum identified this band as GnRH-II receptor-like antigen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16189182     DOI: 10.1530/eje.1.02005

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  Promotion of human trophoblasts invasion by gonadotropin-releasing hormone (GnRH) I and GnRH II via distinct signaling pathways.

Authors:  Jing Liu; Colin D Maccalman; Yan-ling Wang; Peter C K Leung
Journal:  Mol Endocrinol       Date:  2009-04-16

2.  Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.

Authors:  Carsten Gründker; Crispin Föst; Stefanie Fister; Nadine Nolte; Andreas R Günthert; Günter Emons
Journal:  Breast Cancer Res       Date:  2010-07-14       Impact factor: 6.466

Review 3.  Expression and Role of Gonadotropin-Releasing Hormone 2 and Its Receptor in Mammals.

Authors:  Amy T Desaulniers; Rebecca A Cederberg; Clay A Lents; Brett R White
Journal:  Front Endocrinol (Lausanne)       Date:  2017-12-11       Impact factor: 5.555

Review 4.  The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis.

Authors:  Carsten Gründker; Günter Emons
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-04       Impact factor: 5.555

Review 5.  The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer.

Authors:  Günter Emons; Carsten Gründker
Journal:  Cells       Date:  2021-02-01       Impact factor: 6.600

Review 6.  Evaluation of the potential of ultrasound-mediated drug delivery for the treatment of ovarian cancer through preclinical studies.

Authors:  Yi-Chao Wang; Jing-Yan Tian; Ying-Ying Han; Yun-Fei Liu; Si-Yao Chen; Feng-Jun Guo
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.